FDA Panel Endorses Synergo Combo Product For Bladder Cancer
This article was originally published in The Gray Sheet
Executive Summary
Medical Enterprises' Synergo combination product for prevention of bladder cancer recurrence should be approved by FDA, contingent upon a one-year post-approval study to further assess its safety in the U.S. population, according to the agency's Gastroenterology and Urology Devices Panel